clinical trial · NCT07454863
A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)
Lymphoma, Non-HodgkinDZD8586
brief summary
This phase I study is designed to evaluate absorption, metabolism and excretion (AME) profiles of \[14C\]-DZD8586, to determine the routes, rates of elimination, and mass balance of DZD8586 in healthy adult male participants. Participants will be administered a single oral dose of 50 mg of \[14C\]-DZD8586 (containing radioactive dose \~ 100 μCi) as a suspension.
started
Mar 1, 2026
primary completion
Aug 1, 2026
completion
Sep 1, 2026
last updated
Mar 6, 2026
official title
A Phase I, Single-center, Non-randomized, Open-label, Mass Balance Study of Orally Administered [14C]-DZD8586 in Healthy Adult Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol